DexCom (DXCM)
(Delayed Data from NSDQ)
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$72.24 USD
-1.43 (-1.94%)
Updated Aug 27, 2024 03:59 PM ET
After-Market: $72.22 -0.02 (-0.03%) 6:08 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Zacks News
DexCom (DXCM) Beats on Q1 Earnings, Hikes '19 Guidance
by Zacks Equity Research
DexCom's (DXCM) Q1 earnings gain from top-line growth and solid segmental performance. However, contraction in gross margin remains a headwind.
DexCom (DXCM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 70.59% and 13.82%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
DexCom (DXCM) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
DexCom's (DXCM) G6 censors and lucrative collaborations are likely to drive Q1 results.
DexCom (DXCM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Q1 Earnings Top Mark, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) currently concentrates on its core diagnostic information services business and tries to maintain discipline in capital deployment.
Abbott (ABT) Q1 Earnings Beat Estimates, Organic Sales Solid
by Zacks Equity Research
Abbott (ABT) reports strong and consistent EPD and Medical Devices performance organically in Q1.
DexCom (DXCM) Stock Moves 0.35%: What You Should Know
by Zacks Equity Research
DexCom (DXCM) closed the most recent trading day at $119.30, moving +0.35% from the previous trading session.
DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $116.92, marking a -0.2% move from the previous day.
Here's Why You Should Retain ABIOMED Stock in Your Portfolio
by Zacks Equity Research
Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.
Integer Holdings Gets Positive Outlook & B+ Rating From S&P
by Zacks Equity Research
Integer (ITGR) strengthens its balance sheet by reducing its leverage ratio from 5.6X at the end of 2017 to 3.5X at 2018 end.
Why Veeva Systems (VEEV) is an Attractive Pick Right Now?
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio is likely to provide it with a competitive edge in the MedTech space.
Here's Why Investors Should Retain NextGen Healthcare Stock
by Zacks Equity Research
Despite aggressive rivalry in the niche space, NextGen (NXGN) will continue to benefit from strong demand for its other NextGen solutions that include Hospitals, EHR and practice management.
Varian Medical (VAR) Collaborates With Korea-Based Hospital
by Zacks Equity Research
Varian Medical (VAR) has seen notable developments in Asia of late.
Allscripts' FollowMyHealth Partners Ephraim McDowell Health
by Zacks Equity Research
Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.
Fresenius Medical to Make Huge Investments, Competition Rife
by Zacks Equity Research
Fresenius Medical (FMS) is likely to make huge investments in India and China.
AMN Healthcare Down on Soft Locum Tenens Business, Dull View
by Zacks Equity Research
Dependence on third parties is detrimental for AMN Healthcare (AMN).
BD Remains Confident About LUTONIX DCB Despite FDA Letter
by Zacks Equity Research
Per the recent press release issued by BD (BDX), it seems that the company still has immense confidence on the LUTONIX DCB.
DexCom (DXCM) Down 11.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HMS Holdings Gains on PI & TPM Solutions, Competition Rife
by Zacks Equity Research
HMS Holdings is consistently boosting margins and profitability on product-yield enhancements and process improvements.
Here's Why You Should Retain Ecolab Stock in Your Portfolio
by Zacks Equity Research
A solid guidance for 2019 and broad product spectrum will provide Ecolab (ECL) a competitive edge in the MedTech space.
DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day
Bull of the Day: DexCom (DXCM)
by Kevin Cook
Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
Recently, Cerner (CERN) expanded its reach in the Alabama rural health care market through a new collaboration.
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DXCM) Outperforming Other Medical Stocks This Year?
Inogen's Prospects in Europe Solid Amid Trade-Related Tension
by Zacks Equity Research
Inogen's (INGN) business-to-business unit sees strength in Europe.